In vitro breast cancer model with patient-specific morphological features for personalized medicine

In vitro cancer models that can simulate patient-specific drug responses for personalized medicine have attracted significant attention. However, the technologies used to produce such models can only recapitulate the morphological heterogeneity of human cancer tissue. Here, we developed a novel 3D technique to bioprint an in vitro breast cancer model with patient-specific morphological features. This model can precisely mimic the cellular microstructures of heterogeneous cancer tissues and produce drug responses similar to those of human cancers. We established a bioprinting process for generating cancer cell aggregates with ductal and solid tissue microstructures that reflected the morphology of breast cancer tissues, and applied it to develop breast cancer models. The genotypic and phenotypic characteristics of the ductal and solid cancer aggregates bioprinted with human breast cancer cells (MCF7, SKBR3, MDA-MB-231) were respectively similar to those of early and advanced cancers. The bioprinted solid cancer cell aggregates showed significantly higher hypoxia (>8 times) and mesenchymal (>2–4 times) marker expressions, invasion activity (>15 times), and drug resistance than the bioprinted ductal aggregates. Co-printing the ductal and solid aggregates produced heterogeneous breast cancer tissue models that recapitulated three different stages of breast cancer tissue morphology. The bioprinted cancer tissue models representing advanced cancer were more and less resistant, respectively, to the anthracycline antibiotic doxorubicin and the hypoxia-activated prodrug tirapazamine; these were analogous to the results in human cancer. The present findings showed that cancer cell aggregates can mimic the pathological micromorphology of human breast cancer tissue and they can be bioprinted to produce breast cancer tissue in vitro that can morphologically represent the clinical stage of cancer in individual patients.

[1]  S. Boccia,et al.  Success Factors and Barriers in Combining Personalized Medicine and Patient Centered Care in Breast Cancer. Results from a Systematic Review and Proposal of Conceptual Framework , 2021, Journal of personalized medicine.

[2]  G. MacGrogan,et al.  Label-Free Observation of Micrometric Inhomogeneity of Human Breast Cancer Cell Density Using Terahertz Near-Field Microscopy , 2021 .

[3]  Zuowei Zhao,et al.  Optimizing individualized treatment strategy based on breast cancer organoid model , 2021, Clinical and translational medicine.

[4]  R. Minchin,et al.  Hypoxia-mediated drug resistance in breast cancers. , 2020, Cancer letters.

[5]  Hyun-Wook Kang,et al.  High‐Precision 3D Bio‐Dot Printing to Improve Paracrine Interaction between Multiple Types of Cell Spheroids , 2020, Advanced Functional Materials.

[6]  E. Lee,et al.  Abstract 1667: Comparison of drug responses using patient-derived xenograft (PDX) and patient-derived organoid (PDO) models from treatment-refractory breast cancer , 2020, Molecular and Cellular Biology / Genetics.

[7]  Eva Forssell-Aronsson,et al.  Optimization of cell viability assays to improve replicability and reproducibility of cancer drug sensitivity screens , 2020, Scientific Reports.

[8]  H. Park,et al.  Establishment of chemosensitivity tests in triple-negative and BRCA-mutated breast cancer patient-derived xenograft models , 2019, PloS one.

[9]  Xueji Zhang,et al.  A 3D Printed Hanging Drop Dripper for Tumor Spheroids Analysis Without Recovery , 2019, Scientific Reports.

[10]  Peter A Mollica,et al.  3D bioprinted mammary organoids and tumoroids in human mammary derived ECM hydrogels. , 2019, Acta biomaterialia.

[11]  Alan F. Murray,et al.  Development and characterisation of acquired radioresistant breast cancer cell lines , 2019, Radiation Oncology.

[12]  Simon C Watkins,et al.  Targeting the Temporal Dynamics of Hypoxia-Induced Tumor-Secreted Factors Halts Tumor Migration. , 2019, Cancer research.

[13]  S. Kong,et al.  Integrative In Vivo Drug Testing Using Gene Expression Signature and Patient-Derived Xenografts from Treatment-Refractory HER2 Positive and Triple-Negative Subtypes of Breast Cancer , 2019, Cancers.

[14]  M. Gardaneh,et al.  The next generation personalized models to screen hidden layers of breast cancer tumorigenicity , 2019, Breast cancer research and treatment.

[15]  Wei Sun,et al.  Bioprinting of 3D breast epithelial spheroids for human cancer models , 2019, Biofabrication.

[16]  Tiffany M. Heaster,et al.  Organotypic microfluidic breast cancer model reveals starvation-induced spatial-temporal metabolic adaptations , 2018, EBioMedicine.

[17]  Jijun Cheng,et al.  Characterization of drug responses of mini patient-derived xenografts in mice for predicting cancer patient clinical therapeutic response , 2018, Cancer communications.

[18]  Daniel S. Reynolds,et al.  Breast Cancer Spheroids Reveal a Differential Cancer Stem Cell Response to Chemotherapeutic Treatment , 2017, Scientific Reports.

[19]  N. Cherdyntseva,et al.  Intratumoral Morphological Heterogeneity of Breast Cancer As an Indicator of the Metastatic Potential and Tumor Chemosensitivity , 2017, Acta naturae.

[20]  Hanry Yu,et al.  3D Culture as a Clinically Relevant Model for Personalized Medicine , 2017, SLAS technology.

[21]  S. Oesterreich,et al.  Three-Dimensional Breast Cancer Models Mimic Hallmarks of Size-Induced Tumor Progression. , 2016, Cancer research.

[22]  James J. Yoo,et al.  A 3D bioprinting system to produce human-scale tissue constructs with structural integrity , 2016, Nature Biotechnology.

[23]  H. Kleinman,et al.  In Vitro Microtumors Provide a Physiologically Predictive Tool for Breast Cancer Therapeutic Screening , 2015, PloS one.

[24]  Huijun Sun,et al.  Dasatinib reverses the multidrug resistance of breast cancer MCF-7 cells to doxorubicin by downregulating P-gp expression via inhibiting the activation of ERK signaling pathway , 2015, Cancer biology & therapy.

[25]  Pei-Ru Wu,et al.  High nuclear/cytoplasmic ratio of Cdk1 expression predicts poor prognosis in colorectal cancer patients , 2014, BMC Cancer.

[26]  Alex J Walsh,et al.  Quantitative optical imaging of primary tumor organoid metabolism predicts drug response in breast cancer. , 2014, Cancer research.

[27]  W. Wilson,et al.  Dual Targeting of Hypoxia and Homologous Recombination Repair Dysfunction in Triple-Negative Breast Cancer , 2014, Molecular Cancer Therapeutics.

[28]  B. Zhou,et al.  Epithelial-mesenchymal Transition---A Hallmark of Breast Cancer Metastasis. , 2013, Cancer hallmarks.

[29]  Seung Il Kim,et al.  Personalized Medicine in Breast Cancer: A Systematic Review , 2012, Journal of breast cancer.

[30]  Peter A Fasching,et al.  Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment , 2011, BMC Cancer.

[31]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[32]  Shu Ichihara,et al.  Breast cancer prognostic classification in the molecular era: the role of histological grade , 2010, Breast Cancer Research.

[33]  A. Rajasekaran,et al.  Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis. , 2006, Cancer research.

[34]  G. Landberg,et al.  Hypoxia promotes a dedifferentiated phenotype in ductal breast carcinoma in situ. , 2003, Cancer research.

[35]  D. Gheonea,et al.  Preliminary study of correlations between the intratumoral microvessel density and the morphological profile of colorectal carcinoma. , 2015, Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie.